Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
$6.31
-7.5%
$3.36
$2.01
$15.60
$11.55M5.08498,845 shs932,080 shs
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
$1.58
-0.4%
$1.72
$1.21
$2.55
$11.63M75.28143,053 shs43,517 shs
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
$1.17
-1.7%
$1.16
$11.07
$33.08
$4.22M0.2340,215 shs7,770 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19170,086 shs4.12 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.00%+127.76%+95.93%+168.93%+33.47%
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
0.00%-1.61%-12.00%-8.17%-15.29%
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
-2.50%+6.36%-7.14%+2.63%-88.86%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+10.54%-68.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.413 of 5 stars
0.05.00.00.01.10.00.0
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
2.7534 of 5 stars
3.53.00.00.00.63.30.6
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.00
N/AN/AN/A
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
3.00
Buy$18.001,036.36% Upside
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
$9.51M1.19N/AN/A$4.63 per share1.36
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
$400K29.70N/AN/A$1.23 per share1.29
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
-$1.60MN/A0.00N/A-22.85%-24.18%-20.14%N/A
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A

Latest DHAC, ENZ, BRTX, and BGLC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/A-$0.03N/A-$0.03N/AN/A
5/14/2025Q1 2025
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/AN/AN/AN/AN/A
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
N/AN/AN/AN/AN/A
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/A
4.19
3.44
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
N/A
2.24
2.24
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28

Institutional Ownership

CompanyInstitutional Ownership
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
18.85%
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
69.38%
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
1.01%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%

Insider Ownership

CompanyInsider Ownership
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.70%
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
25.50%
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
6.59%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
301.80 million1.78 millionNot Optionable
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
77.50 million5.59 millionNot Optionable
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
2,0213.60 million3.37 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable

Recent News About These Companies

ENZB - Enzo Biochem Inc Dividends - Morningstar
Enzo Biochem: Fiscal Q3 Earnings Snapshot
Enzo Biochem, Inc. (ENZB)
Enzo Biochem transitions to OTCQX market
OTC Markets Group Welcomes Enzo Biochem, Inc. to OTCQX
Top Research Reports for AbbVie, TJX & Charles Schwab

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNexus Gene Lab stock logo

BioNexus Gene Lab NASDAQ:BGLC

$6.31 -0.51 (-7.49%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$6.33 +0.02 (+0.32%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Biorestorative Therapies stock logo

Biorestorative Therapies NASDAQ:BRTX

$1.58 -0.01 (-0.38%)
As of 07/3/2025 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Digital Health Acquisition stock logo

Digital Health Acquisition NASDAQ:DHAC

$1.17 -0.02 (-1.68%)
As of 07/3/2025

Digital Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on technology and healthcare focused businesses. Digital Health Acquisition Corp. was incorporated in 2021 and is based in Boca Raton, Florida.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.